House Patent Reform Bill: Battle Looms Over Patent Reexamination Provisions
This article was originally published in The Gray Sheet
Executive SummaryThe six-year battle over patent reform legislation is not yet over as the device and drug industries and other leading industry stakeholders are unhappy with provisions in the House bill that differ from the recently passed Senate measure.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.